Clayface is DC's cheapest, riskiest test: can Gunn sell a monster?

What happens when a superhero universe stops selling superheroes? We're about to find out. Clayface, the R-rated body horror film from James Watkins, opens in North America this weekend, and it may be the most revealing release James Gunn and Peter Safran have put out so far, precisely because nobody expects it to be a blockbuster.

The facts are simple. Clayface opened internationally on October 21 and reaches North America on October 23, according to IGN. Tracking has wobbled: Bam Smack Pow reports a domestic projection of $15–20 million, down from earlier estimates of $23–33 million. It also reports a budget of around $30 million, though other outlets say $40 million. Either way, it's tiny next to the $160 million budget Bam Smack Pow cites for Supergirl, which GeekTyrant says grossed just $126.4 million worldwide.

The number to watch isn't the opening, it's the legs

Opening-weekend headlines will compare Clayface with superhero tentpoles, and that's the wrong yardstick. A film this cheap can lose the weekend and still win the month. The recent horror hits cited in the coverage, Obsession and Backrooms, didn't launch huge. They built slowly through word of mouth. We think that's the template Clayface needs: a modest start, a small drop, and a calendar that looks lighter the following weekend.

That's why the second weekend will tell us more than the first. If the drop is steep, the DCU will have shown it can't turn curiosity into a crowd without a famous name. If it holds, it will have shown something more valuable: that the brand can support a mid-budget lane, a place for weird, adult, director-driven projects. That lane is where we'd bet the long-term health of this universe lies.

Reviews say "bold," not "great," and that matters

Critics are split. IGN calls it a fun, gritty throwback to body horror, with shades of The Fly and Darkman. Deadline says it's for "the horror junkies." The Guardian, by contrast, calls it a middling attempt with a tinny, TV-like look. IndieWire, for its part, credits the DCU for making interesting choices but finds the film confounds more than it compels.

Even IGN, which likes the film, says it barely feels like a DC movie and could just as easily have been set outside the DCU. In our view, that cuts both ways. It's a strength if you want proof that the label can host genre cinema. It's a weakness if the label is supposed to be what gets people into theaters. A casual viewer who doesn't know Clayface from any other Batman villain has little reason to buy a ticket, and Box Office Pro's own warning, quoted by GeekTyrant, is that this crossover audience needs strong marketing or word of mouth.

What a "win" should look like for Gunn

The comparison that comes to mind is Joker, a darker, cheaper villain story that crossed $1 billion. Clayface isn't going to do that, and it would be unfair to expect it to. The Guardian says Gunn would clearly like to emulate that path financially, not for awards. We'd set a humbler bar: recoup the budget quickly, hold well, and avoid becoming a punchline.

There's a real risk in the other direction, too. If Clayface performs adequately but gets dismissed as a one-off oddity, the studio might retreat to capes and icons, the safest and most expensive path. If it works, "Gods and Monsters" gets a template: small bets, clear genre identity, and a price tag that allows failure. That's a healthier model than a universe where every release has to rescue the franchise.

So our recommendation? If you like practical-effects horror and don't mind squirm-inducing scenes, go see it in a theater this weekend, and don't treat the DC label as a promise of anything. And if you're tracking the DCU's future, ignore the opening number. Watch the drop.